ATE366731T1 - Pyrrolidin- und thiazolidin-derivate, deren darstellung und anwendung zur behandlung von hyperglykämie und typ ii diabetes - Google Patents

Pyrrolidin- und thiazolidin-derivate, deren darstellung und anwendung zur behandlung von hyperglykämie und typ ii diabetes

Info

Publication number: ATE366731T1
Authority: AT; Austria
Prior art keywords: hyperglycemia; pyrrolidine; diabetes; preparation; treatment
Prior art date: 2004-05-19

Application number

AT05291066T

Other languages

English (en)

Inventor

Nanteuil Guillaume De

Alain Benoist

Murielle Combettes

Elizabeth Harley

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-19

Filing date

2005-05-18

Publication date

2007-08-15

2005-05-18 Application filed by Servier Lab filed Critical Servier Lab

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE366731T1 publication Critical patent/ATE366731T1/de

Links

RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 3
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical class C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 title 1
201000001421 hyperglycemia Diseases 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Pyrrole Compounds (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT05291066T 2004-05-19 2005-05-18 Pyrrolidin- und thiazolidin-derivate, deren darstellung und anwendung zur behandlung von hyperglykämie und typ ii diabetes ATE366731T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0405454A FR2870538B1 (fr)	2004-05-19	2004-05-19	Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number	Publication Date
ATE366731T1 true ATE366731T1 (de)	2007-08-15

Family

ID=34942306

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05291066T ATE366731T1 (de)	2004-05-19	2005-05-18	Pyrrolidin- und thiazolidin-derivate, deren darstellung und anwendung zur behandlung von hyperglykämie und typ ii diabetes

Country Status (28)

Country	Link
US (1)	US7439263B2 (de)
EP (1)	EP1598350B1 (de)
JP (1)	JP4335171B2 (de)
KR (1)	KR100747967B1 (de)
CN (1)	CN100381438C (de)
AR (1)	AR049278A1 (de)
AT (1)	ATE366731T1 (de)
AU (1)	AU2005202180B2 (de)
BR (1)	BRPI0501769A (de)
CA (1)	CA2506491C (de)
CY (1)	CY1106878T1 (de)
DE (1)	DE602005001576T2 (de)
DK (1)	DK1598350T3 (de)
EA (1)	EA009292B1 (de)
ES (1)	ES2290864T3 (de)
FR (1)	FR2870538B1 (de)
GE (1)	GEP20074103B (de)
HR (1)	HRP20070376T3 (de)
MX (1)	MXPA05005256A (de)
MY (1)	MY139481A (de)
NO (1)	NO330294B1 (de)
NZ (1)	NZ540108A (de)
PL (1)	PL1598350T3 (de)
PT (1)	PT1598350E (de)
RS (1)	RS50526B (de)
SG (1)	SG117551A1 (de)
SI (1)	SI1598350T1 (de)
ZA (1)	ZA200504050B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2020413A1 (de)	2007-08-02	2009-02-04	Bayer CropScience AG	Oxaspirocyclische-spiro-substituierte Tetram- und Tetronsäure-Derivate
US8338450B2 (en) *	2007-09-21	2012-12-25	Lupin Limited	Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
CA2712352C (en) *	2008-01-23	2016-05-10	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Dicycloazaalkane derivates, preparation processes and medical uses thereof
WO2010146597A1 (en)	2009-06-18	2010-12-23	Lupin Limited	2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
US8440710B2 (en) *	2009-10-15	2013-05-14	Hoffmann-La Roche Inc.	HSL inhibitors useful in the treatment of diabetes
US9567300B2 (en)	2012-06-25	2017-02-14	Sunshine Lake Pharma Co., Ltd.	Hexahydropentaleno derivatives, preparation method and use in medicine thereof
KR102449196B1 (ko)	2016-01-15	2022-09-29	삼성전자주식회사	비휘발성 메모리 장치 및 비휘발성 메모리 장치의 프로그램 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0618957B2 (ja) *	1988-01-26	1994-03-16	日本合成化学工業株式会社	成形物の製造方法
CA2046801C (en) *	1990-08-07	2002-02-26	Peter D. Davis	Substituted pyrroles
DE4222459C2 (de) *	1992-07-08	1995-09-14	Sigma Tau Ind Farmaceuti	3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
EP0706527B1 (de) *	1993-07-02	2001-11-14	Bayer Ag	Substituierte spiroheterocyclische 1h-3-aryl-pyrrolidin-2,4-dion-derivate, verfahren zu deren herstellung und deren verwendung als schädlingsbekämpfungsmittel
TW492957B (en) *	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW583185B (en) *	2000-06-13	2004-04-11	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
JP4101053B2 (ja) *	2000-08-10	2008-06-11	田辺三菱製薬株式会社	プロリン誘導体及びその医薬用途
WO2002024697A1 (en) *	2000-09-25	2002-03-28	Toray Industries, Inc.	Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
FR2824825B1 (fr) *	2001-05-15	2005-05-06	Servier Lab	Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002360732A1 (en) *	2001-12-26	2003-07-24	Guilford Pharmaceuticals	Change inhibitors of dipeptidyl peptidase iv
HUP0200849A2 (hu) *	2002-03-06	2004-08-30	Sanofi-Synthelabo	N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
WO2003084940A1 (en) *	2002-04-08	2003-10-16	Alangudi Sankaranarayanan	Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
TW200404796A (en) *	2002-08-19	2004-04-01	Ono Pharmaceutical Co	Nitrogen-containing compound
US7262207B2 (en) *	2002-09-19	2007-08-28	Abbott Laboratories	Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
CA2504735C (en) *	2002-11-07	2009-06-23	Merck & Co., Inc.	Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

2004
- 2004-05-19 FR FR0405454A patent/FR2870538B1/fr not_active Expired - Fee Related
2005
- 2005-05-04 SG SG200502766A patent/SG117551A1/en unknown
- 2005-05-05 CA CA002506491A patent/CA2506491C/fr not_active Expired - Fee Related
- 2005-05-17 MX MXPA05005256A patent/MXPA05005256A/es active IP Right Grant
- 2005-05-18 ES ES05291066T patent/ES2290864T3/es not_active Expired - Lifetime
- 2005-05-18 GE GEAP20058802A patent/GEP20074103B/en unknown
- 2005-05-18 PL PL05291066T patent/PL1598350T3/pl unknown
- 2005-05-18 AR ARP050102045A patent/AR049278A1/es unknown
- 2005-05-18 KR KR1020050041742A patent/KR100747967B1/ko not_active Expired - Fee Related
- 2005-05-18 RS RSP-2007/0392A patent/RS50526B/sr unknown
- 2005-05-18 EP EP05291066A patent/EP1598350B1/de not_active Expired - Lifetime
- 2005-05-18 PT PT05291066T patent/PT1598350E/pt unknown
- 2005-05-18 MY MYPI20052248A patent/MY139481A/en unknown
- 2005-05-18 US US11/131,510 patent/US7439263B2/en not_active Expired - Fee Related
- 2005-05-18 NZ NZ540108A patent/NZ540108A/en unknown
- 2005-05-18 AT AT05291066T patent/ATE366731T1/de active
- 2005-05-18 SI SI200530030T patent/SI1598350T1/sl unknown
- 2005-05-18 DK DK05291066T patent/DK1598350T3/da active
- 2005-05-18 EA EA200500683A patent/EA009292B1/ru not_active IP Right Cessation
- 2005-05-18 DE DE602005001576T patent/DE602005001576T2/de not_active Expired - Lifetime
- 2005-05-19 BR BR0501769-6A patent/BRPI0501769A/pt not_active IP Right Cessation
- 2005-05-19 CN CNB200510087845XA patent/CN100381438C/zh not_active Expired - Fee Related
- 2005-05-19 JP JP2005146186A patent/JP4335171B2/ja not_active Expired - Fee Related
- 2005-05-19 ZA ZA200504050A patent/ZA200504050B/en unknown
- 2005-05-19 AU AU2005202180A patent/AU2005202180B2/en not_active Ceased
- 2005-05-19 NO NO20052414A patent/NO330294B1/no not_active IP Right Cessation
2007
- 2007-09-03 HR HR20070376T patent/HRP20070376T3/xx unknown
- 2007-09-19 CY CY20071101205T patent/CY1106878T1/el unknown

Also Published As

Publication number	Publication date
MXPA05005256A (es)	2005-11-24
CA2506491C (fr)	2009-09-01
DE602005001576D1 (de)	2007-08-23
MY139481A (en)	2009-10-30
RS50526B (sr)	2010-05-07
US7439263B2 (en)	2008-10-21
SG117551A1 (en)	2005-12-29
ZA200504050B (en)	2006-07-26
AR049278A1 (es)	2006-07-12
CN1721417A (zh)	2006-01-18
EP1598350A1 (de)	2005-11-23
EP1598350B1 (de)	2007-07-11
NZ540108A (en)	2006-04-28
HRP20070376T3 (en)	2007-12-31
CN100381438C (zh)	2008-04-16
EA200500683A1 (ru)	2005-12-29
JP4335171B2 (ja)	2009-09-30
NO20052414L (no)	2005-11-21
HK1086259A1 (zh)	2006-09-15
KR100747967B1 (ko)	2007-08-08
BRPI0501769A (pt)	2006-01-10
PL1598350T3 (pl)	2007-10-31
CA2506491A1 (fr)	2005-11-19
DK1598350T3 (da)	2007-11-12
SI1598350T1 (sl)	2007-10-31
NO20052414D0 (no)	2005-05-19
AU2005202180B2 (en)	2010-10-28
FR2870538B1 (fr)	2006-07-14
FR2870538A1 (fr)	2005-11-25
JP2005350456A (ja)	2005-12-22
ES2290864T3 (es)	2008-02-16
NO330294B1 (no)	2011-03-21
US20050261501A1 (en)	2005-11-24
AU2005202180A1 (en)	2005-12-08
PT1598350E (pt)	2007-10-04
EA009292B1 (ru)	2007-12-28
DE602005001576T2 (de)	2008-04-17
CY1106878T1 (el)	2012-09-26
KR20060048007A (ko)	2006-05-18
GEP20074103B (en)	2007-05-10

Publication	Publication Date	Title
EP1758597A4 (de)	2008-02-27	Verwendung von arzneimittelkombinationen zur behandlung der insulinresistenz
DE602007005487D1 (de)	2010-05-06	Harnstoffderivate von tropan, ihre herstellung und ihre therapeutische anwendung
ATE395342T1 (de)	2008-05-15	2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
DE602005002470D1 (de)	2007-10-25	1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
DE602004022946D1 (de)	2009-10-15	4-cyanopyrazol-3-carbonsäureamidderivate, herstellung und therapeutische anwendung davon
DE60030109D1 (de)	2006-09-28	(-)(3-trihalomethylphenoxy) (4-halophenyl) zur behandlung von insulinresistenz und typ ii diabetes
ATE512970T1 (de)	2011-07-15	Dimere von artemisininderivaten, deren herstellung und deren therapeutische verwendung
DE50312295D1 (de)	2010-02-11	8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
DE502007005708D1 (de)	2010-12-30	3 -amino- imidazo ä1,2-aüpyridinderivate mit sglt1 und sglt2 hemmender wirkung zur behandlung von diabetes vom typ 1 und typ 2
EP1991055A4 (de)	2012-08-29	Formulierungen, die ein nichtoxidatives biozid und eine quelle von aktivem halogen enthalten, und ihre verwendung bei der behandlung von wasser
DE602005027546D1 (de)	2011-06-01	Aryl- und heteroarylpiperidincarboxylatderivate, deren herstellung und deren verwendung in form von faah-enzyminhibitoren
ATE447570T1 (de)	2009-11-15	Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen
DE60307632D1 (de)	2006-09-28	Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
DE602005023884D1 (de)	2010-11-11	Wässrige grundierungszusammensetzung, oberflächenbehandlungsverfahren unter verwendung derselben und mehrschichtige struktur
DE602006017980D1 (de)	2010-12-16	3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
ATE412635T1 (de)	2008-11-15	Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
ATE438623T1 (de)	2009-08-15	Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
ATE502035T1 (de)	2011-04-15	2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE504595T1 (de)	2011-04-15	Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz
ATE366731T1 (de)	2007-08-15	Pyrrolidin- und thiazolidin-derivate, deren darstellung und anwendung zur behandlung von hyperglykämie und typ ii diabetes
DE602006020713D1 (de)	2011-04-28	Alkyl-, alkenyl- und alkynylcarbamat-derivate, deren herstellung und therapeutische verwendung
DE602005011450D1 (de)	2009-01-15	N-(1 h-indolyl)-1 h- indol-2-carboxamid-derivate, deren herstellung und therapeutische verwendung damit
DE602004003751D1 (de)	2007-02-01	Heterocyclische Oximderivate, Verfahren zu ihrer Herstellung und Verwendung in der Behandlung von Typ II Diabetes
DE602004019809D1 (de)	2009-04-16	Pharmazeutische zusammensetzung, vinflunin enthaltend, zur parenteralen verabreichung, deren herstellungsverfahren und anwendung
ATE499351T1 (de)	2011-03-15	Aryl- und heteroaryl-ethyl-acylguanidinderivate, ihre herstellung und ihre therapeutische anwendung